## Mark Opler

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9370608/publications.pdf

Version: 2024-02-01

623734 552781 44 738 14 26 citations h-index g-index papers 46 46 46 1131 citing authors all docs docs citations times ranked

#	Article	IF	CITATIONS
1	Electromagnetic field exposure induces rapid, transitory heat shock factor activation in human cells. Journal of Cellular Biochemistry, 1997, 66, 482-488.	2.6	98
2	Is lead exposure in early life an environmental risk factor for Schizophrenia? Neurobiological connections and testable hypotheses. NeuroToxicology, 2012, 33, 560-574.	3.0	82
3	Prenatal stress and affective disorders in a population birth cohort. Bipolar Disorders, 2013, 15, 92-99.	1.9	61
4	A new brief opioid stigma scale to assess perceived public attitudes and internalized stigma: Evidence for construct validity. Journal of Substance Abuse Treatment, 2019, 99, 44-51.	2.8	47
5	Later paternal age and sex differences in schizophrenia symptoms. Schizophrenia Research, 2010, 116, 191-195.	2.0	42
6	Olfactory processing, sex effects and heterogeneity in schizophrenia. Schizophrenia Research, 2012, 135, 144-151.	2.0	37
7	Autism Behavior Inventory: A Novel Tool for Assessing Core and Associated Symptoms of Autism Spectrum Disorder. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 814-822.	1.3	37
8	Biological and technical variables in myc expression in HL60 cells exposed to 60 Hz electromagnetic fields. Bioelectrochemistry, 1997, 44, 111-120.	1.0	31
9	Prostate Cancer in Fathers With Fewer Male Offspring: the Jerusalem Perinatal Study Cohort. Journal of the National Cancer Institute, 2007, 99, 77-81.	6.3	22
10	A new Integrated Negative Symptom structure of the Positive and Negative Syndrome Scale (PANSS) in schizophrenia using item response analysis. Schizophrenia Research, 2013, 150, 185-196.	2.0	20
11	Assessing the Sources of Unreliability (Rater, Subject, Time-Point) in a Failed Clinical Trial Using Items of the Positive and Negative Syndrome Scale (PANSS). Journal of Clinical Psychopharmacology, 2013, 33, 109-117.	1.4	17
12	The brief negative symptom scale (BNSS): Sensitivity to treatment effects. Schizophrenia Research, 2018, 197, 269-273.	2.0	17
13	Inter-rater reliability of ratings on the six-item Positive and Negative Syndrome Scale (PANSS-6) obtained using the Simplified Negative and Positive Symptoms Interview (SNAPSI). Nordic Journal of Psychiatry, 2018, 72, 431-436.	1.3	17
14	Validity and Reliability of the Arabic Version of the Positive and Negative Syndrome Scale. Psychopathology, 2016, 49, 181-187.	1.5	16
15	Risk of schizophrenia and minority status: A comparison of the Swedish-speaking minority and the Finnish-speaking majority in Finland. Schizophrenia Research, 2014, 159, 303-308.	2.0	15
16	Validation of the Arabic Version of Calgary Depression Scale for Schizophrenia. PLoS ONE, 2016, 11, e0162304.	2.5	15
17	Reduced dopamine levels in PC12 cells exposed to low frequency electromagnetic fields. Bioelectrochemistry, 1997, 42, 235-239.	1.0	14
18	Clinical Validation of the Autism Behavior Inventory: Caregiver-Rated Assessment of Core and Associated Symptoms of Autism Spectrum Disorder. Journal of Autism and Developmental Disorders, 2020, 50, 2090-2101.	2.7	14

#	Article	IF	CITATIONS
19	The brief negative symptom scale in translation: A review of psychometric properties and beyond. European Neuropsychopharmacology, 2020, 33, 36-44.	0.7	14
20	Emotional and Neurobehavioural Status in Chronic Pain Patients. Pain Research and Management, 2011, 16, 41-43.	1.8	13
21	Primary psychiatric prevention in children and adolescents. Annals of Clinical Psychiatry, 2010, 22, 220-34.	0.6	13
22	Environmental Risk Factors and Schizophrenia. International Journal of Mental Health, 2013, 42, 23-32.	1.3	11
23	Job Burnout, Mood State, and Cardiovascular Variable Changes of Doctors and Nurses in a Children's Hospital in China. ISRN Nursing, 2014, 2014, 1-6.	1.2	11
24	Consistency checks to improve measurement with the Positive and Negative Syndrome Scale (PANSS). Schizophrenia Research, 2017, 190, 74-76.	2.0	11
25	Clinical validation of ratings on the six-item Positive and Negative Syndrome Scale obtained via the Simplified Negative and Positive Symptoms Interview. Journal of Psychopharmacology, 2021, 35, 1081-1090.	4.0	9
26	Effect of parental age on treatment response in adolescents with schizophrenia. Schizophrenia Research, 2013, 151, 185-190.	2.0	8
27	Validation of the Five-Factor Model of the Arabic Version of the Positive and Negative Syndrome Scale in Schizophrenia. Psychopathology, 2017, 50, 211-218.	1.5	7
28	Reliability, validity and factorial structure of the Arabic version of the international suicide prevention trial (InterSePT) scale for suicidal thinking in schizophrenia patients in Doha, Qatar. BMC Psychiatry, 2016, 16, 437.	2.6	6
29	Cross-cultural adaptation of the Arabic Positive and Negative Syndrome Scale in schizophrenia: Qualitative analysis of a focus group. Transcultural Psychiatry, 2019, 56, 973-991.	1.6	6
30	Consistency checks to improve measurement with the Personal and Social Performance Scale (PSP). Schizophrenia Research, 2021, 228, 529-533.	2.0	6
31	Clinical validation of the Symptom Self-rating Scale for Schizophrenia (4S) among inpatients. Nordic Journal of Psychiatry, 2021, 75, 454-464.	1.3	5
32	Abnormal phospholipid metabolism in schizophrenia: evidence from epidemiological findings, clinical observations, and preliminary clinical trials. Frontiers in Bioscience - Landmark, 2001, 6, e61.	3.0	3
33	ADVANCED PATERNAL AGE CONTRIBUTES TO A SPECIFIC SUBTYPE OF SCHIZOPHRENIA. Schizophrenia Research, 2012, 136, S3.	2.0	2
34	Comments on the scoring guideline of the Personal and Social Performance Scale (PSP). Schizophrenia Research, 2014, 152, 304.	2.0	2
35	T22. CLINICAL VALIDATION OF THE SIX-ITEM POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS-6). Schizophrenia Bulletin, 2019, 45, S211-S212.	4.3	2
36	M35. CLINICAL VALIDATION OF THE SIX-ITEM POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS-6). Schizophrenia Bulletin, 2020, 46, S147-S148.	4.3	2

#	Article	IF	CITATIONS
37	Standardized training in the rating of the six-item Positive And Negative Syndrome Scale (PANSS-6). Schizophrenia Research, 2021, 228, 438-446.	2.0	2
38	Secretin's role in the cerebellum: A larger biological context and implications for developmental disorders. Cerebellum, 2006, 5, 2-6.	2.5	1
39	Discrepancies between staff and gold standard ratings of schizophrenia symptom severity. Psychiatry Research, 2021, 301, 113963.	3.3	1
40	Poster #188 A RASCH MODEL ANALYSIS TO ASSESS CROSS-CULTURAL DIFFERENCES AMONG ITEMS THE POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS) IN SCHIZOPHRENIA. Schizophrenia Research, 2012, 136, S253.	2.0	0
41	177. Autism Behavior Inventory – A Novel Tool for Assessment of Changes in Core and Associated Symptoms of Autism Spectrum Disorder. Biological Psychiatry, 2017, 81, S73-S74.	1.3	0
42	T45. THE NEW YORK ASSESSMENT OF ADVERSE COGNITIVE EFFECTS OF NEUROPSYCHIATRIC TREATMENT (NY-AACENT): INITIAL VALIDATION FINDINGS. Schizophrenia Bulletin, 2019, 45, S221-S221.	4.3	0
43	S244. RELIABILITY OF CORE SCHIZOPHRENIA SYMPTOMS RATINGS USING THE SIX-ITEM POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS-6) PERFORMED BY MEDICAL STUDENTS. Schizophrenia Bulletin, 2020, 46, S131-S132.	4.3	0
44	Epidemiology Research and Epigenetics: Translational Epidemiology of Schizophrenia., 2011,, 71-96.		0